{
  "week": "2026-W38",
  "label": "Week 38 \u2014 September 20\u201326, 2026",
  "week_start": "2026-09-20",
  "generated": "2026-09-21",
  "stats": {
    "total_entries": 1322,
    "new_this_week": 37,
    "compounds_represented": 4
  },
  "by_compound": {
    "psilocybin": [
      {
        "id": "4d4b84e3f04cc4803dbf895b8af7956952171d6e8846116e86ddf759f08191aa",
        "title": "Psychedelics and suicidality: A double-edged sword - risks, mechanisms, and moving forward.",
        "compound": "psilocybin",
        "type": "meta_analysis",
        "institution": null,
        "condition": "other",
        "sample_size": null,
        "status": "published",
        "date": "2026-09-19",
        "abstract": "Classic psychedelics, including lysergic acid diethylamide (LSD), psilocybin, and dimethyltryptamine (DMT), have re-emerged as promising treatments for psychiatric conditions linked to suicidality.\u2026",
        "outcome_summary": null,
        "doi": "10.1016/j.euroneuro.2026.113878",
        "url": "https://pubmed.ncbi.nlm.nih.gov/42762543/",
        "source": "PubMed",
        "first_seen": "2026-09-21",
        "relevance": {
          "relevant": true,
          "reason": "Psychedelics for psychiatric conditions linked to suicidality.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-09-21"
        }
      },
      {
        "id": "d80ee52257b350caf0f02b4f1ddb1cf481e6761334a3cc0c913ca5189f662126",
        "title": "A national approach in a European context: Multidisciplinary and multiprofessional recommendations on the clinical use of psychedelic substances.",
        "compound": "psilocybin",
        "type": "phase_2",
        "institution": null,
        "condition": "other",
        "sample_size": null,
        "status": "published",
        "date": "2026-01-01",
        "abstract": "The therapeutic benefits of psychedelics for neuropsychiatric conditions have gathered significant attention in Europe and around the world, with treatments using psilocybin, MDMA, and ketamine as notable examples.\u2026",
        "outcome_summary": null,
        "doi": "10.1016/j.nsa.2026.107028",
        "url": "https://pubmed.ncbi.nlm.nih.gov/42761569/",
        "source": "PubMed",
        "first_seen": "2026-09-21",
        "relevance": {
          "relevant": true,
          "reason": "Recommendations on clinical use of psychedelics for neuropsychiatric conditions.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-09-21"
        }
      },
      {
        "id": "978009b120fab066b752729cc17e5fb336034c190be56154ca78bcbac52fce85",
        "title": "Perceptions and Attitudes on Psilocybin-Assisted Therapy among Underrepresented People with Cancer.",
        "compound": "psilocybin",
        "type": "phase_2",
        "institution": null,
        "condition": "other",
        "sample_size": null,
        "status": "published",
        "date": "2026-09-18",
        "abstract": "Psilocybin-assisted therapy (PAT) shows promise for alleviating psychological and existential distress among people with cancer; however, research is limited by homogeneous samples, raising concerns about generalizability and equity.\u2026",
        "outcome_summary": null,
        "doi": "10.1016/j.jpainsymman.2026.09.018",
        "url": "https://pubmed.ncbi.nlm.nih.gov/42759904/",
        "source": "PubMed",
        "first_seen": "2026-09-21",
        "relevance": {
          "relevant": true,
          "reason": "Psilocybin for psychological distress in cancer patients.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-09-21"
        }
      },
      {
        "id": "88080955bbce93c699bfa6db25163c68a53674d6702a31abd5afa28eed3618e4",
        "title": "A Case of Acute Mania and Rhabdomyolysis Associated With Long-Term, Daily Psilocybin Use.",
        "compound": "psilocybin",
        "type": "phase_2",
        "institution": null,
        "condition": "other",
        "sample_size": null,
        "status": "published",
        "date": "2026-09-21",
        "abstract": null,
        "outcome_summary": null,
        "doi": "10.1097/JCP.0000000000002262",
        "url": "https://pubmed.ncbi.nlm.nih.gov/42758023/",
        "source": "PubMed",
        "first_seen": "2026-09-21",
        "relevance": {
          "relevant": true,
          "reason": "Adverse event associated with psilocybin use in humans.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-09-21"
        }
      },
      {
        "id": "2efeb793ab32e3063b2e4da3ace4514caca062ce78ffc663b50d48071d8d55a0",
        "title": "High ventilation breathwork as a non-pharmacological model for inducing psychedelic-like states: expert evaluations of therapeutic potential and risk.",
        "compound": "psilocybin",
        "type": "phase_2",
        "institution": null,
        "condition": "other",
        "sample_size": null,
        "status": "published",
        "date": "2026-09-17",
        "abstract": "High ventilation breathwork (HVB) can induce altered states of consciousness with phenomenological similarities to those reported following administration of serotonergic psychedelics such as lysergic acid diethylamide (LSD), psilocybin or ayahuasca.\u2026",
        "outcome_summary": null,
        "doi": "10.1038/s44184-026-00246-x",
        "url": "https://pubmed.ncbi.nlm.nih.gov/42754646/",
        "source": "PubMed",
        "first_seen": "2026-09-21",
        "relevance": {
          "relevant": true,
          "reason": "non-pharmacological model for psychedelic-like states",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-09-21"
        }
      },
      {
        "id": "8f4b45c5a7049c9b98e0f4c6bb4146a24321ccdc2cf4ca2f28f416cbe051c387",
        "title": "Surrender, disidentification, and reappraisal: a qualitative comparison of psilocybin responders and non-responders in treatment-resistant OCD.",
        "compound": "psilocybin",
        "type": "phase_2",
        "institution": null,
        "condition": "OCD",
        "sample_size": null,
        "status": "published",
        "date": "2026-01-01",
        "abstract": "Psilocybin treatment has shown promise for treatment-resistant obsessive-compulsive disorder (OCD), yet clinical response is variable. Little is known about the subjective experiences associated with divergent outcomes or the psychological processes differentiating responders from non-responders.\u2026",
        "outcome_summary": null,
        "doi": "10.3389/fpsyt.2026.1791689",
        "url": "https://pubmed.ncbi.nlm.nih.gov/42746496/",
        "source": "PubMed",
        "first_seen": "2026-09-21",
        "relevance": {
          "relevant": true,
          "reason": "Psilocybin for treatment-resistant OCD in humans.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-09-21"
        }
      },
      {
        "id": "35cb212cf0a0d219e602796a535efa70cb415980ea5c94535c8f41aeb35f4c08",
        "title": "Resetting the hippocampal buffer: a neurocognitive account of psychedelic therapy for anxiety-related psychopathology.",
        "compound": "psilocybin",
        "type": "meta_analysis",
        "institution": null,
        "condition": "anxiety",
        "sample_size": null,
        "status": "published",
        "date": "2026-09-15",
        "abstract": "Psychedelics (hallucinogenic 5-HT2A agonists such as psilocybin) are being investigated for their potential to treat a range of conditions, including anxiety-related psychopathology. Despite promising results, the mechanisms by which psychedelic therapy may alleviate anxiety are not well understood.\u2026",
        "outcome_summary": null,
        "doi": "10.1007/s00213-026-07163-z",
        "url": "https://pubmed.ncbi.nlm.nih.gov/42742718/",
        "source": "PubMed",
        "first_seen": "2026-09-21",
        "relevance": {
          "relevant": true,
          "reason": "Psychedelics for anxiety-related psychopathology and neurocognitive mechanisms.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-09-21"
        }
      },
      {
        "id": "411a6fbcb8ff55a212001bb4534ad0ee788458e67b13d191eac72d29e5950ba1",
        "title": "Safety and Efficacy of Natural and Conventional Psychiatric Treatments: A Comparative Review of Mushroom-Derived Compounds and Medicinal Plants in the Management of Mental Disorders.",
        "compound": "psilocybin",
        "type": "meta_analysis",
        "institution": null,
        "condition": "depression",
        "sample_size": null,
        "status": "published",
        "date": "2026-09-07",
        "abstract": "Standard pharmacotherapy for mental disorders, including depression and anxiety, is supported by extensive clinical validation and international treatment guidelines. However, it is frequently associated with limitations such as adverse side effects, low patient adherence, and the risk of relapse.\u2026",
        "outcome_summary": null,
        "doi": "10.3390/molecules31173130",
        "url": "https://pubmed.ncbi.nlm.nih.gov/42738789/",
        "source": "PubMed",
        "first_seen": "2026-09-21",
        "relevance": {
          "relevant": true,
          "reason": "Review of mushroom compounds for mental disorders like depression and anxiety.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-09-21"
        }
      },
      {
        "id": "4786fed2b8ec0ee254f73f1f6f36bbe2b9236a69d5f2919858989abdd5b52e44",
        "title": "Implications of Potential US FDA Approval of Psychedelics or Psychedelic-Adjacents Such as Ibogaine for Pharmacy in Japan.",
        "compound": "psilocybin",
        "type": "meta_analysis",
        "institution": null,
        "condition": "depression",
        "sample_size": null,
        "status": "published",
        "date": "2026-09-01",
        "abstract": "An Executive Order signed in April 2026 directed US federal agencies to expedite development and review pathways for psychedelic and psychedelic-adjacent (such as ibogaine) therapies.\u2026",
        "outcome_summary": null,
        "doi": "10.7759/cureus.116178",
        "url": "https://pubmed.ncbi.nlm.nih.gov/42733721/",
        "source": "PubMed",
        "first_seen": "2026-09-21",
        "relevance": {
          "relevant": true,
          "reason": "Regulatory and policy news regarding psychedelic therapies.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-09-21"
        }
      },
      {
        "id": "e270af725d75c5fbac2e837f134cf34d0038f26bfe5adf31b2b0b2e198c3e991",
        "title": "Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Randomized Controlled Trial",
        "compound": "psilocybin",
        "type": "phase_2",
        "institution": "University Health Network, Toronto",
        "condition": "other",
        "sample_size": 46,
        "status": "recruiting",
        "date": "2026-09-14",
        "abstract": "Phase II randomized controlled trial, followed by an open-label extension phase. In the main study, participants will receive either a single high-dose (25 mg) or low-dose (1 mg) of psilocybin in the context of Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy.\u2026",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT07820033",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-09-21",
        "relevance": {
          "relevant": true,
          "reason": "Psilocybin for end-of-life existential distress in cancer patients.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-09-21"
        }
      },
      {
        "id": "5892803a66e0445ef98caec6267a48dff55ffd24a5ab702fd10861bfd4f55311",
        "title": "Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study",
        "compound": "psilocybin",
        "type": "phase_1",
        "institution": "Imperial College London",
        "condition": "eating_disorder",
        "sample_size": 21,
        "status": "completed",
        "date": "2021-05-28",
        "abstract": "The primary aim of this study is to assess the acceptability and efficacy of treating anorexia nervosa with psilocybin.\u2026",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT04505189",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-09-21",
        "relevance": {
          "relevant": true,
          "reason": "Psilocybin for anorexia nervosa, a psychiatric indication.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-09-21"
        }
      },
      {
        "id": "2368381fbd5120e8b193a8d5cb200badc20456e3923b7ae524e9789a465e1c3d",
        "title": "Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin",
        "compound": "psilocybin",
        "type": "phase_2",
        "institution": "National Institute on Aging (NIA)",
        "condition": "other",
        "sample_size": 200,
        "status": "recruiting",
        "date": "2026-10-01",
        "abstract": "Normal aging, as well as dementias such as Alzheimer s disease, can cause changes in the brain that affect memory, attention, and thinking. Researchers want to know if regular mental tasks (cognitive training) can improve brain function in older adults.\u2026",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT07721467",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-09-21",
        "relevance": {
          "relevant": true,
          "reason": "Psilocybin used to enhance cognitive training for aging/dementia.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-09-21"
        }
      },
      {
        "id": "e40667aaaf9e4ec9916172e32256eea64bdfbe485fa07c5997869112a15b75da",
        "title": "Investor Relations",
        "compound": "psilocybin",
        "type": "news",
        "institution": "Compass Pathways plc",
        "condition": "depression",
        "sample_size": null,
        "status": "other",
        "date": "2026-08-04",
        "abstract": "treatment and has Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA), as well as Innovative Licensing and Access Pathway (ILAP) designation in the UK for TRD.\u2026",
        "outcome_summary": "Compass Pathways is a biotechnology company developing COMP360 psilocybin for treatment-resistant depression and PTSD. They are leading a clinical program in TRD and executing a late-stage trial for PTSD.",
        "doi": null,
        "url": "https://ir.compasspathways.com/overview/default.aspx",
        "source": "Compass Pathways",
        "first_seen": "2026-09-21",
        "relevance": {
          "relevant": true,
          "reason": "Biotech company developing psilocybin for depression and PTSD.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-09-21"
        }
      }
    ],
    "ketamine": [
      {
        "id": "834ea75f86e2cde68561495c2def2bd427ee25ccc547b1136738631672e055c4",
        "title": "A circuit dissection of perception-action decoupling in S-ketamine-induced hallucination-like states.",
        "compound": "ketamine",
        "type": "phase_2",
        "institution": null,
        "condition": "other",
        "sample_size": null,
        "status": "published",
        "date": "2026-09-19",
        "abstract": "Hallucinations are a core feature of several psychiatric disorders, but the circuit mechanisms that separate perception from behavioral output remain poorly defined.\u2026",
        "outcome_summary": null,
        "doi": "10.1038/s41380-026-03893-w",
        "url": "https://pubmed.ncbi.nlm.nih.gov/42763341/",
        "source": "PubMed",
        "first_seen": "2026-09-21",
        "relevance": {
          "relevant": true,
          "reason": "S-ketamine used for hallucination-like states in humans.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-09-21"
        }
      },
      {
        "id": "ac7b91c22e16057688372cb6673bc8dd4b9be05b194613ee31ea5a311bb77982",
        "title": "Cognitive effects of ketamine and esketamine treatment for major depressive and bipolar disorder: a systematic review.",
        "compound": "ketamine",
        "type": "meta_analysis",
        "institution": null,
        "condition": "depression",
        "sample_size": null,
        "status": "published",
        "date": "2026-09-14",
        "abstract": "Cognitive impairment is a core feature of major depressive disorder (MDD) and bipolar disorder (BD). Most conventional antidepressants do not have direct and clinically relevant procognitive effects. Ketamine and esketamine are effective in treating treatment-resistant depression (TRD).\u2026",
        "outcome_summary": null,
        "doi": "10.1016/j.psychres.2026.117456",
        "url": "https://pubmed.ncbi.nlm.nih.gov/42762641/",
        "source": "PubMed",
        "first_seen": "2026-09-21",
        "relevance": {
          "relevant": true,
          "reason": "Systematic review of ketamine/esketamine for depression cognitive effects.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-09-21"
        }
      },
      {
        "id": "d05b8b9af7de27bdc2750017c5abd254a93e1d38f71fec2d37e9d0f7f9c8f226",
        "title": "Intravenous Ketamine for Treatment-Resistant Depression: A Case Report From a Public Hospital in Argentina.",
        "compound": "ketamine",
        "type": "phase_2",
        "institution": null,
        "condition": "depression",
        "sample_size": null,
        "status": "published",
        "date": "2026-04-01",
        "abstract": "Treatment-resistant depression (TRD) is a severe form of depression associated with high rates of disability and suicide, underscoring the need for effective therapeutic alternatives.\u2026",
        "outcome_summary": null,
        "doi": null,
        "url": "https://pubmed.ncbi.nlm.nih.gov/42762051/",
        "source": "PubMed",
        "first_seen": "2026-09-21",
        "relevance": {
          "relevant": true,
          "reason": "Ketamine for treatment-resistant depression in humans.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-09-21"
        }
      },
      {
        "id": "4c12552e217dcd8a0bbd701c260b40766962aac386c81d99138a31e562bf873c",
        "title": "New treatments for treatment-resistant depression: esketamine controversies - a narrative review.",
        "compound": "ketamine",
        "type": "meta_analysis",
        "institution": null,
        "condition": "depression",
        "sample_size": null,
        "status": "published",
        "date": "2026-08-04",
        "abstract": "This narrative review examines barriers to Danish patients' timely access to new treatments for treatment-resistant depression, focusing on controversies around esketamine. Delays arise from regulatory complexity, economic constraints and scientific debate over novel psychotropics.\u2026",
        "outcome_summary": null,
        "doi": "10.61409/A02260078",
        "url": "https://pubmed.ncbi.nlm.nih.gov/42757607/",
        "source": "PubMed",
        "first_seen": "2026-09-21",
        "relevance": {
          "relevant": true,
          "reason": "Review of esketamine for treatment-resistant depression",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-09-21"
        }
      },
      {
        "id": "4cb29ebdf2754ff7ed244b3cef3941dfade9d24b857d116e5fa7a2729063a8f8",
        "title": "Short-term ketamine interventions for depressive disorders: practical best-practice recommendations for psychiatrists using oral, subcutaneous, and nasal formulations.",
        "compound": "ketamine",
        "type": "meta_analysis",
        "institution": null,
        "condition": "depression",
        "sample_size": null,
        "status": "published",
        "date": "2026-01-01",
        "abstract": "Ketamine and esketamine are increasingly used for treatment-resistant depressive disorders, particularly when rapid symptom reduction is clinically desirable.\u2026",
        "outcome_summary": null,
        "doi": "10.3389/fpsyt.2026.1931248",
        "url": "https://pubmed.ncbi.nlm.nih.gov/42756688/",
        "source": "PubMed",
        "first_seen": "2026-09-21",
        "relevance": {
          "relevant": true,
          "reason": "Ketamine for depressive disorders, not anesthesia.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-09-21"
        }
      },
      {
        "id": "b23f8c64ec0a8a7bad8b18f11e521f9c48e870889bd666a120467a68d58fd9d1",
        "title": "Risk of ketamine exposure in individuals at clinical high-risk for psychosis.",
        "compound": "ketamine",
        "type": "phase_2",
        "institution": null,
        "condition": "other",
        "sample_size": null,
        "status": "published",
        "date": "2026-09-17",
        "abstract": null,
        "outcome_summary": null,
        "doi": "10.1016/j.schres.2026.09.019",
        "url": "https://pubmed.ncbi.nlm.nih.gov/42753482/",
        "source": "PubMed",
        "first_seen": "2026-09-21",
        "relevance": {
          "relevant": true,
          "reason": "Investigational treatment for psychiatric indications.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-09-21"
        }
      },
      {
        "id": "1d00806c3c4851196e8069ba824336af8787bfe34e6ed95db2bc93bd205dc24a",
        "title": "Esketamine for treatment of depression in Huntington's disease: A case report.",
        "compound": "ketamine",
        "type": "phase_2",
        "institution": null,
        "condition": "depression",
        "sample_size": null,
        "status": "published",
        "date": "2026-09-17",
        "abstract": "Depression and suicidal ideation are common in Huntington's disease (HD). We report a 60-year-old male with HD who suffered from treatment-resistant depression with intermittent suicidal thoughts for 20 years, irritability and apathy.\u2026",
        "outcome_summary": null,
        "doi": "10.1177/18796397261489245",
        "url": "https://pubmed.ncbi.nlm.nih.gov/42752279/",
        "source": "PubMed",
        "first_seen": "2026-09-21",
        "relevance": {
          "relevant": true,
          "reason": "Esketamine for depression in Huntington's disease is a psychiatric indication.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-09-21"
        }
      },
      {
        "id": "4ff5bb69b12fc1f9eec46ef4e21c0303158df9e91562c6ec662359b111c2678f",
        "title": "[Intravenous ketamine in suicidal crisis : indications and patient referral].",
        "compound": "ketamine",
        "type": "meta_analysis",
        "institution": null,
        "condition": "depression",
        "sample_size": null,
        "status": "published",
        "date": "2026-09-16",
        "abstract": "Intravenous (IV) ketamine is a rapidly acting therapeutic option for the management of treatment-resistant depression and acute suicidal crisis. Unlike conventional antidepressants, its effects may occur within hours, allowing a rapid reduction in suicidal ideation and psychological distress.\u2026",
        "outcome_summary": null,
        "doi": "10.53738/REVMED.2026.22.975.49121",
        "url": "https://pubmed.ncbi.nlm.nih.gov/42750580/",
        "source": "PubMed",
        "first_seen": "2026-09-21",
        "relevance": {
          "relevant": true,
          "reason": "Ketamine for suicidal crisis and depression.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-09-21"
        }
      },
      {
        "id": "5b882d2d72dc2f34c7851df46c896cab7c6c30c90561a4d6816dc13e30aca1fb",
        "title": "Clinical correlates of non-responders to ketamine in terms of self-assessed life engagement among treatment-resistant depression patients.",
        "compound": "ketamine",
        "type": "phase_2",
        "institution": null,
        "condition": "depression",
        "sample_size": null,
        "status": "published",
        "date": "2026-09-10",
        "abstract": "Major depressive and bipolar disorders are leading causes of disability, with many patients developing treatment-resistant depression (TRD/TRBD). Ketamine offers rapid symptom relief, yet recovery extends beyond symptoms.\u2026",
        "outcome_summary": null,
        "doi": "10.1016/j.jpsychires.2026.09.003",
        "url": "https://pubmed.ncbi.nlm.nih.gov/42748866/",
        "source": "PubMed",
        "first_seen": "2026-09-21",
        "relevance": {
          "relevant": true,
          "reason": "Ketamine for treatment-resistant depression patients.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-09-21"
        }
      },
      {
        "id": "d04abbf78efa773873d73a9feabbbef07a5afbd235b487172a6a04afe0a31242",
        "title": "Ketamine Dose and Duration Effects in Internalizing Disorders.",
        "compound": "ketamine",
        "type": "phase_2",
        "institution": null,
        "condition": "depression",
        "sample_size": null,
        "status": "published",
        "date": "2026-09-01",
        "abstract": "The dose-response profile of racemic ketamine in internalizing disorders is poorly characterized. This was a secondary analysis of outcome responses in patients with treatment-resistant depression, post-traumatic stress disorder, generalized and/or social anxiety, or obsessive-compulsive disorder.\u2026",
        "outcome_summary": null,
        "doi": "10.1002/jcph.70299",
        "url": "https://pubmed.ncbi.nlm.nih.gov/42746802/",
        "source": "PubMed",
        "first_seen": "2026-09-21",
        "relevance": {
          "relevant": true,
          "reason": "Ketamine for internalizing disorders like depression, PTSD, anxiety, OCD.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-09-21"
        }
      },
      {
        "id": "3dcc93b405036fe24c4b2902174b7b22371e81b17b3a80943ff70e921ab42137",
        "title": "Ketamine attenuates habenula activity in response to aversive outcomes during Pavlovian learning.",
        "compound": "ketamine",
        "type": "phase_2",
        "institution": null,
        "condition": "depression",
        "sample_size": null,
        "status": "published",
        "date": "2026-09-15",
        "abstract": "Ketamine is an NMDA receptor antagonist with rapid antidepressant properties when administered at a subanesthetic dose.\u2026",
        "outcome_summary": null,
        "doi": "10.1016/j.cub.2026.08.044",
        "url": "https://pubmed.ncbi.nlm.nih.gov/42743922/",
        "source": "PubMed",
        "first_seen": "2026-09-21",
        "relevance": {
          "relevant": true,
          "reason": "Ketamine's antidepressant properties and effects on brain activity in humans.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-09-21"
        }
      },
      {
        "id": "d26a8e28d1eb0200796cab49b92cc7a4ce091f7b647a2f12fd61d682e71ecba4",
        "title": "Real-World Effectiveness and Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: A Retrospective Observational Study.",
        "compound": "ketamine",
        "type": "phase_2",
        "institution": null,
        "condition": "depression",
        "sample_size": null,
        "status": "published",
        "date": "2026-08-26",
        "abstract": "Background/Objectives: This study evaluated the real-world effectiveness and safety of intranasal esketamine plus oral antidepressants compared with venlafaxine-based oral antidepressant therapy in adults with moderate-to-severe treatment-resistant depression (TRD).\u2026",
        "outcome_summary": null,
        "doi": "10.3390/healthcare14172717",
        "url": "https://pubmed.ncbi.nlm.nih.gov/42736875/",
        "source": "PubMed",
        "first_seen": "2026-09-21",
        "relevance": {
          "relevant": true,
          "reason": "Esketamine for treatment-resistant depression in humans.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-09-21"
        }
      },
      {
        "id": "083b0157f43bc3f79bed95765b22c80fdf5ab61c98904c38cf47ba477e27c599",
        "title": "Rectal Prolapse Associated With Chronic Ketamine Misuse: A Report of Two Cases.",
        "compound": "ketamine",
        "type": "phase_2",
        "institution": null,
        "condition": "other",
        "sample_size": null,
        "status": "published",
        "date": "2026-08-01",
        "abstract": "Chronic ketamine misuse is a well-recognized cause of ketamine-induced uropathy (KIU), characterized by severe lower urinary tract symptoms and markedly reduced bladder capacity. Its potential association with anorectal dysfunction remains poorly described.\u2026",
        "outcome_summary": null,
        "doi": "10.7759/cureus.114526",
        "url": "https://pubmed.ncbi.nlm.nih.gov/42733537/",
        "source": "PubMed",
        "first_seen": "2026-09-21",
        "relevance": {
          "relevant": true,
          "reason": "Chronic ketamine misuse and its complications in humans.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-09-21"
        }
      },
      {
        "id": "82d7e2eee1b1a9c9991aaa20c8abb6f7aea43988ada2b09313908090979e08c2",
        "title": "Ketamine IV Classic Protocol : Five Years Follow up",
        "compound": "ketamine",
        "type": "observational",
        "institution": "Sheba Medical Center",
        "condition": "depression",
        "sample_size": 11,
        "status": "completed",
        "date": "2019-08-08",
        "abstract": "Patients who suffer from MDD recieved ketamnie (2014-15) in open study will be addressed and there depression mood will be evaluated using the rating scale that were used in the original research. In addition time of relapse and questions about their medications and drug use will be performed.",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT04824157",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-09-21",
        "relevance": {
          "relevant": true,
          "reason": "Ketamine for MDD, human study, long-term follow-up.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-09-21"
        }
      },
      {
        "id": "5ecb7496ae3d02696173779c5e024c835db62dda1ba5d25398b0ed6053ae558b",
        "title": "Mitochondrial Function After Ketamine",
        "compound": "ketamine",
        "type": "observational",
        "institution": "Sheba Medical Center",
        "condition": "depression",
        "sample_size": 30,
        "status": "recruiting",
        "date": "2026-02-01",
        "abstract": "The goal of this observational study is to learn about the role of mitochondria in response to S-ketamine. in individuals with Treatment-Resistant Depression. the Research Questions are 1.\u2026",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT07399756",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-09-21",
        "relevance": {
          "relevant": true,
          "reason": "Observational study on S-ketamine for treatment-resistant depression.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-09-21"
        }
      },
      {
        "id": "16213140cb425f0471b5869ed7676b720b3014137f9951747ec54d53fb943af0",
        "title": "Ketamine for the Treatment of Opioid Use Disorder and Depression",
        "compound": "ketamine",
        "type": "phase_2",
        "institution": "Medical University of South Carolina",
        "condition": "depression",
        "sample_size": 21,
        "status": "completed",
        "date": "2020-12-17",
        "abstract": "The purpose of the study is to examine whether an investigational medication called ketamine is able to improve treatment outcomes for concurrent opioid addiction and depression when used in conjunction with buprenorphine treatment. Study medications will be delivered twice per week for four weeks.\u2026",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT04177706",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-09-21",
        "relevance": {
          "relevant": true,
          "reason": "Ketamine for opioid use disorder and depression in humans.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-09-21"
        }
      },
      {
        "id": "98a1f8db77d9b90d89d8ea691c84366224748ee4b1cfdb1d8122960c6ff9e73b",
        "title": "Pilot Study of Ketamine in Adults With Obsessive-Compulsive Disorder (OCD)",
        "compound": "ketamine",
        "type": "phase_2",
        "institution": "New York State Psychiatric Institute",
        "condition": "OCD",
        "sample_size": 15,
        "status": "completed",
        "date": "2010-04-01",
        "abstract": "In this study investigators are studying the effects of a drug called ketamine on the symptoms of Obsessive-compulsive disorder (OCD).",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT01100255",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-09-21",
        "relevance": {
          "relevant": true,
          "reason": "Ketamine for psychiatric indication (OCD).",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-09-21"
        }
      },
      {
        "id": "dab90e689212e1ac7b02a2568b5f990c71c7b774192f8081f0fee794f41d0699",
        "title": "Multiple Dose Pharmacokinetics of Intranasal Ketamine",
        "compound": "ketamine",
        "type": "phase_1",
        "institution": "Javelin Pharmaceuticals",
        "condition": "other",
        "sample_size": 18,
        "status": "completed",
        "date": "2007-06-01",
        "abstract": "This is an open label, single-center study of the pharmacokinetic and safety profile of repeat doses of PMI-150 (intranasal ketamine) 30 mg in healthy adult volunteers.",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT00519987",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-09-21",
        "relevance": {
          "relevant": true,
          "reason": "Pharmacokinetics of intranasal ketamine in healthy volunteers.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-09-21"
        }
      },
      {
        "id": "4aab3a9ac1d560a59ebf5619eb378f91524afd60964dd81d435db163a4e781d3",
        "title": "Ketamine for MS Fatigue",
        "compound": "ketamine",
        "type": "observational",
        "institution": "Alta Bates Summit Medical Center",
        "condition": "other",
        "sample_size": 21,
        "status": "completed",
        "date": "2023-12-05",
        "abstract": "The purpose of this study is to see whether using ketamine to increase glutamate in the prefrontal cortex can reduce Multiple Sclerosis (MS) related fatigue.\u2026",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT06064162",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-09-21",
        "relevance": {
          "relevant": true,
          "reason": "Ketamine for chronic pain (MS fatigue) in humans.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-09-21"
        }
      },
      {
        "id": "08b9f54b074cc5262d7a454d870a46e76b101d5e24ac05efe689c242f4be3472",
        "title": "Imaging Depression in Parkinson's Disease",
        "compound": "ketamine",
        "type": "phase_2",
        "institution": "Yale University",
        "condition": "depression",
        "sample_size": 120,
        "status": "recruiting",
        "date": "2024-09-01",
        "abstract": "The goal of this observational study is to identify targetable neural substrates of depression in Parkinson's Disease for the first time in people with Parkinson's between the ages of 40 and 80, who are experiencing symptoms of depression.",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT06402955",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-09-21",
        "relevance": {
          "relevant": true,
          "reason": "Observational study of depression in Parkinson's disease patients.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-09-21"
        }
      },
      {
        "id": "f59306d0bed85a47a38f388c11ecb8de0e5a678f9ec5b27f9f01b70ea2acaa0b",
        "title": "Ketamine as a Rapidly-Acting Antidepressant in Depressed Emergency Department Patients",
        "compound": "ketamine",
        "type": "phase_2",
        "institution": "NYU Langone Health",
        "condition": "depression",
        "sample_size": 21,
        "status": "completed",
        "date": "2013-12-01",
        "abstract": "Investigators will conduct a trial to evaluate the use of Ketamine as an alternate treatment for people with Major Depressive Disorder.\u2026",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT02106325",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-09-21",
        "relevance": {
          "relevant": true,
          "reason": "Ketamine for depression in humans.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-09-21"
        }
      }
    ],
    "dmt": [
      {
        "id": "b82dced4c004aa3603c4c543d47ad23ea8b3555e8941ed7465688b5e2ec29f02",
        "title": "Defining the intervention before estimating efficacy in DMT-assisted therapy.",
        "compound": "dmt",
        "type": "phase_2",
        "institution": null,
        "condition": "other",
        "sample_size": null,
        "status": "published",
        "date": "2026-09-17",
        "abstract": null,
        "outcome_summary": null,
        "doi": "10.1177/02698811261488484",
        "url": "https://pubmed.ncbi.nlm.nih.gov/42752265/",
        "source": "PubMed",
        "first_seen": "2026-09-21",
        "relevance": {
          "relevant": true,
          "reason": "DMT-assisted therapy for psychiatric indications.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-09-21"
        }
      }
    ],
    "other": [
      {
        "id": "b2d688877831dfa6526fc2315ed626b58e49987dbc3503f6f4e7182bdc6d58e1",
        "title": "On the meaning of \"plasticity\" in neuroscience and mental health research and its relation to the action of psychedelic therapy.",
        "compound": "other",
        "type": "phase_2",
        "institution": null,
        "condition": "other",
        "sample_size": null,
        "status": "published",
        "date": "2026-01-01",
        "abstract": "First-line dictionary definitions of \"plasticity\" describe it as the ability (of a thing) to be shaped or molded; we call this \"plasticity proper\" (PP). In neuroscience, however, \"neural plasticity\" or \"neuroplasticity\" is defined as an induced change in brain function or structure.\u2026",
        "outcome_summary": null,
        "doi": "10.3389/fnins.2026.1875339",
        "url": "https://pubmed.ncbi.nlm.nih.gov/42745840/",
        "source": "PubMed",
        "first_seen": "2026-09-21",
        "relevance": {
          "relevant": true,
          "reason": "Discusses plasticity in relation to psychedelic therapy.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-09-21"
        }
      },
      {
        "id": "5365b2a4d32312e4a92011ef10b8757d3c8360fcd6c8b4a69a8ea0b056114d96",
        "title": "FDA Hearing on Psychedelic Medicine Reveals a Field Divided on the Road to Approval",
        "compound": "other",
        "type": "news",
        "institution": null,
        "condition": "other",
        "sample_size": null,
        "status": "other",
        "date": "2026-09-15",
        "abstract": "psilocybin ### New Phase 2 Clinical Trial Initiating in 2027: Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder Cheung/Adobe Stock ### Glyph Allopregnanolone for Major Depressive Disorder Meets Phase 1 Endpoints psychedelic ### New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial: The Power of Another COMP360 Dose ## Latest CME Jersey City Psychiatry ## Jersey City Psychiatry October 2-3, 2026 [...] Director Marta Sokolowska framed the session as part of a \u201cwhole of government effort\u201d following the April 2026 executive order on accelerating treatments for serious mental illness, the FDA\u2019s finalized clinical-investigation guidance, and 3 national priority vouchers issued to sponsors studying psilocybin and methylone.\u00b9 While the hearing explicitly excluded discussion of individual drug applications, the clinical testimony converged on several recurring tensions.\u2026",
        "outcome_summary": "An FDA hearing on psychedelic medicine highlighted debates regarding administration protocols, proving efficacy, and tracking safety as approvals approach. While enthusiasm exists to address unmet needs, there is a lack of consensus on execution, with discussions covering access, clinical usefulness, administration, and safety.",
        "doi": null,
        "url": "https://www.psychiatrictimes.com/view/fda-hearing-on-psychedelic-medicine-reveals-a-field-divided-on-the-road-to-approval",
        "source": "General News",
        "first_seen": "2026-09-21",
        "relevance": {
          "relevant": true,
          "reason": "FDA hearing on psychedelic medicine and regulatory approval",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-09-21"
        }
      }
    ]
  }
}